论文部分内容阅读
目的评价地特胰岛素联合阿卡波糖治疗口服降糖药失效的老年T2DM的有效性和安全性。方法将60例口服降糖药失效的老年T2DM患者,随机分为地特胰岛素联合阿卡波糖组和预混人胰岛素(诺和灵30R)组进行治疗,观察治疗前后的FBG、2hBG、HbA1c、C-P、BMI、低血糖发生率、胰岛素用量。结果治疗后,两组患者的FBG、2hBG、HbA1c均较基线显著降低(P<0.05),两组间差异无统计学意义(P>0.05);但地特胰岛素组在胰岛素用量、低血糖发生率、体重增加方面均低于诺和灵30R组(P<0.05),C-P水平明显升高(P<0.05)。结论地特胰岛素与阿卡波糖联合治疗方案对于老年T2DM患者安全、有效、方便,低血糖发生率小,地特胰岛素可改善胰岛功能。
Objective To evaluate the efficacy and safety of detemir plus acarbose in the treatment of elderly patients with T2DM with oral hypoglycemic agents. Methods A total of 60 elderly T2DM patients with oral hypoglycemic agents were randomly divided into insulin detemir plus acarbose group and pre-mixed insulin (norepinephrine 30R) group. FBG, 2hBG, HbA1c , CP, BMI, incidence of hypoglycemia, insulin dosage. Results After treatment, FBG, 2hBG and HbA1c in both groups were significantly lower than those in baseline (P <0.05), but there was no significant difference between the two groups (P> 0.05). However, the insulin dosage and insulin Rate and weight gain were lower than those of Norvuling 30R group (P <0.05), CP level was significantly higher (P <0.05). Conclusion The combination of detemir and acarbose is safe, effective and convenient for patients with T2DM. The incidence of hypoglycemia is small, and insulin detemir can improve the function of islets.